Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.390
-0.130 (-2.88%)
At close: Apr 28, 2026, 4:00 PM EDT
4.620
+0.230 (5.24%)
After-hours: Apr 28, 2026, 7:54 PM EDT
Prelude Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Prelude Therapeutics stock have an average target of 5.67, with a low estimate of 3.00 and a high estimate of 8.00. The average target predicts an increase of 29.16% from the current stock price of 4.39.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Prelude Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $8 | Strong Buy | Maintains | $5 → $8 | +82.23% | Apr 27, 2026 |
| Citizens | Citizens | Buy Maintains $3 → $6 | Buy | Maintains | $3 → $6 | +36.67% | Mar 11, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +13.90% | Sep 23, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $4 → $3 | Buy | Maintains | $4 → $3 | -31.66% | Aug 18, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +13.90% | May 5, 2025 |
Financial Forecast
Revenue This Year
51.00M
from 12.14M
Increased by 320.10%
Revenue Next Year
102.00M
from 51.00M
Increased by 100.00%
EPS This Year
-0.71
from -1.29
EPS Next Year
-0.75
from -0.71
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 105.0M | 105.0M | ||||||
| Avg | 51.0M | 102.0M | ||||||
| Low | n/a | 98.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 764.9% | 105.9% | ||||||
| Avg | 320.1% | 100.0% | ||||||
| Low | - | 92.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.30 | -0.46 | |
| Avg | -0.71 | -0.75 | |
| Low | -1.09 | -1.01 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.